Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic double-stranded DNA serves as the molecular target for SG3199, a pyrrolobenzodiazepine (PBD) dimer. SG3199 forms covalent interstrand cross-links within the minor groove of DNA, primarily at guanine bases, disrupting DNA replication and transcription, leading to cell cycle arrest and apoptosis. Its effectiveness is influenced by factors like ERCC1 and SLFN11 expression levels in tumor cells. SG3199 is a component of antibody-drug conjugates like Tesirine.
Covalent minor groove binding; induces interstrand cross-links, blocking replication and transcription.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic double-stranded DNA (DNA).